Alzinova Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
ALZ
- Share Price
-
$0.29
- (As of Friday Closing)
Alzinova General Information
Description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
- Erik Dahlbergsgatan 11 A
- 411 26 Gothenburg
- Sweden
+46 070-428 00 00
Alzinova Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.29 | $0.29 | $0.09 - $0.52 | $9.3M | 32.4M | 220K | -$0.04 |
Alzinova Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 22 | 7,327 | 12,995 | 6,804 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,116) | (876) | (705) | (653) |
| Net Income | (1,118) | (879) | (705) | (654) |
| Total Assets | 10,314 | 10,132 | 12,290 | 6,795 |
| Total Debt | 0 | 88 | 98 | 86 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Alzinova Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alzinova Patents
Alzinova Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2683738-A1 | Anti oligomer antibodies and uses thereof | Active | 08-Mar-2011 | 000000000 | |
| EP-2683738-B1 | Anti oligomer antibodies and uses thereof | Active | 08-Mar-2011 | 000000000 | |
| EP-2497782-A1 | Anti oligomer antibodies and uses thereof | Inactive | 08-Mar-2011 | 000000000 | 0 |
| US-9062102-B2 | Anti oligomer antibodies and uses thereof | Active | 08-Mar-2011 | 000000000 | |
| US-20130344089-A1 | Anti oligomer antibodies and uses thereof | Active | 08-Mar-2011 | C07K16/18 |
Alzinova Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Håkan Skogström | Chief Financial Officer | ||
| Anders Sandberg | Chief Scientific Officer | ||
| Anders Bylock | Chief Medical Officer | ||
| Kristina Torfgård Ph.D | Chief Executive Officer |
Alzinova Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Alzinova Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|